Key result
Therapeutic rtPA generates kinins in vitro via plasmin-mediated bradykinin release, explaining rtPA-associated angioedema.
This in vitro study demonstrates that rtPA generates bradykinin via a plasmin-mediated pathway, providing a biochemical mechanism for rtPA-associated angioedema in stroke patients.
No takes yet. Share an insight, caveat, or question.
Provides mechanistic insight into rtPA angioedema; leaves open whether pathway targeting reduces clinical risk in stroke thrombolysis.
Molinaro et al. (2002) studied Angioedema associated with rtPA treatment of acute ischemic stroke. Recombinant tissue plasminogen activator (rtPA) was evaluated on Kinin-forming capacity and generation of bradykinin. In vitro, rtPA at therapeutic concentrations generates significant quantities of kinins from human plasma via plasmin-mediated release of bradykinin, explaining rtPA-associated angioedema.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: